{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=68",
    "query": {
      "condition": "Safety Study",
      "page": 68
    },
    "page_size": 10
  },
  "pagination": {
    "page": 68,
    "page_size": 10,
    "total_count": 33598,
    "total_pages": 3360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=69&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Safety+Study&page=67&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-19T16:11:40.781Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00659750",
      "title": "To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rhinitis, Allergic, Perennial"
      ],
      "interventions": [
        {
          "name": "Ciclesonide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 418,
      "start_date": "2003-12",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2016-12-02",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 23,
      "location_summary": "Encinitas, California • Long Beach, California • Los Angeles, California + 19 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00659750"
    },
    {
      "nct_id": "NCT00962091",
      "title": "Study of MLN8237 in Participants With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Alisertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 53,
      "start_date": "2009-09-25",
      "completion_date": "2014-07-01",
      "has_results": true,
      "last_update_posted_date": "2019-03-12",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00962091"
    },
    {
      "nct_id": "NCT00496860",
      "title": "Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Progressive Metastatic Malignancies"
      ],
      "interventions": [
        {
          "name": "ALT-801",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Altor BioScience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2007-05",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-07-22",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 4,
      "location_summary": "Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00496860"
    },
    {
      "nct_id": "NCT03804060",
      "title": "REperfusion With Cooling in CerebraL Acute IscheMia II",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Thermogard XP3",
          "type": "DEVICE"
        },
        {
          "name": "Recanalization only",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "ZOLL Circulation, Inc., USA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 90,
      "start_date": "2019-05-23",
      "completion_date": "2024-05-01",
      "has_results": false,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 8,
      "location_summary": "Marietta, Georgia • Honolulu, Hawaii • Chicago, Illinois + 4 more",
      "locations": [
        {
          "city": "Marietta",
          "state": "Georgia"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03804060"
    },
    {
      "nct_id": "NCT07009678",
      "title": "Comparison of Lower vs Upper Extremity Injection Agitated Saline to Identify Patent Foramen Ovale With Echocardiography",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Patent Foramen Ovale",
        "Cryptogenic Stroke",
        "Embolic Infarction"
      ],
      "interventions": [
        {
          "name": "intravenous access in greater saphenous vein compared to upper extremity site.",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "St. John's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-03-01",
      "completion_date": "2025-05-12",
      "has_results": false,
      "last_update_posted_date": "2025-06-06",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 1,
      "location_summary": "Maple Grove, Minnesota",
      "locations": [
        {
          "city": "Maple Grove",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07009678"
    },
    {
      "nct_id": "NCT06526208",
      "title": "Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorder",
        "Anxiety"
      ],
      "interventions": [
        {
          "name": "MB-IMP",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Southwest Autism Research & Resource Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 108,
      "start_date": "2025-05-28",
      "completion_date": "2027-09-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06526208"
    },
    {
      "nct_id": "NCT00141817",
      "title": "Study Evaluating Pantoprazole in Children With GERD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gastroesophageal Reflux"
      ],
      "interventions": [
        {
          "name": "pantoprazole for approximately 9 weeks.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "1 Year to 11 Years"
      },
      "enrollment_count": 41,
      "start_date": "2005-08",
      "completion_date": "2007-11",
      "has_results": true,
      "last_update_posted_date": "2011-12-28",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 23,
      "location_summary": "Little Rock, Arkansas • Orange, California • San Diego, California + 19 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141817"
    },
    {
      "nct_id": "NCT07145918",
      "title": "A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Emraclidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 268,
      "start_date": "2025-08-04",
      "completion_date": "2028-02",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 7,
      "location_summary": "Little Rock, Arkansas • Glendale, California • Los Alamitos, California + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Gaithersburg",
          "state": "Maryland"
        },
        {
          "city": "Marlton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07145918"
    },
    {
      "nct_id": "NCT05080218",
      "title": "COVID-19 VaccinE Response in Rheumatology Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Psoriatic Arthritis",
        "Spondylarthritis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "TNF Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Canakinumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Curtis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 841,
      "start_date": "2021-11-15",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05080218"
    },
    {
      "nct_id": "NCT03377790",
      "title": "Cantharidin Application in Molluscum Patients-1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Molluscum Contagiosum"
      ],
      "interventions": [
        {
          "name": "VP-102 - Cantharidin, Topical Film Forming Solution",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo -Topical Film Forming Solution without VP-102",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Verrica Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2018-03-21",
      "completion_date": "2018-11-26",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-11-19T16:11:40.781Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Little Rock, Arkansas + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03377790"
    }
  ]
}